



Evaluation of Inhibition of UDP-Glucuronosyltransferase (UGT) 1A1 by Demethylzeylasteral

Ming-Lian YU¹, Jia-Ji LIN², Yue YANG^{3*}, Wen-Jing ZHANG⁴,
Miao-Chun BAI⁵, Cong-Min WANG⁶ & Yue-Ling GUO¹

¹ Department of Pharmacy, The Military General Hospital of Beijing PLA, Beijing, 100700, China.

² Department of Oral Medicine, Fourth Military University, Xi'an, Shanxi, China

³ Faculty of Business Administration, Shenyang Pharmaceutical University, Shenyang, 110016, China

⁴ The department of Gynecology & Obstetrics, The Military General Hospital of Beijing PLA, Beijing, 100700, China.

⁵ The Second Outpatient Services Unit, The Military General Hospital of Beijing PLA, Beijing, 100700, China.

⁶ Department of Dermatology, The Military General Hospital of Beijing PLA, Beijing, 100700, China.

SUMMARY. Many severe clinical adverse effects can be induced through inhibition of UDP-glucuronosyltransferase (UGT) 1A1, including clinical drug-drug interactions (DDI) and metabolic disorders of endogenous substances. The present study aims to investigate the inhibition of UGT1A1 by demethylzeylasteral which is an important bioactive component isolated from *Tripterygium wilfordii* Hook F. Recombinant UGT1A1 was used as enzyme source, and 4-methylumbelliferone (4-MU) was employed as probe substrate. The results showed that the residual activity of 4-MU glucuronidation was 8.5 ± 1.1 % of the control activity at 100 μ M of demethylzeylasteral for UGT1A1. Furthermore, inhibition kinetic type and parameters were evaluated. Dixon plot and Lineweaver-Burk plot showed that demethylzeylasteral non-competitively inhibited UGT1A1, and the inhibition parameter (K_i) was determined to be 21.7 μ M for UGT1A1. This kind of inhibitory effect need much attention when demethylzeylasteral and demethylzeylasteral-containing herbs (e.g. *Tripterygium wilfordii* Hook F.) were co-administered with the drugs mainly undergoing UGT1A1-catalyzed metabolism.

KEY WORDS: Demethylzeylasteral, Drug-drug interaction, UDP-glucuronosyltransferase (UGT) 1A1.

*Author to whom correspondence should be addressed. E-mail: Yuminglian137@163.com